UK Approves Treatment for Sleep Onset Insomnia in Children and Adolescents
The UK’s MHRA has approved Colonis’ melatonin oral solution for sleep onset insomnia in children and adolescents with ADHD.
Colonis, a subsidiary company of the Clinigen Group, announced on Oct. 4, 2022 that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its melatonin 1mg/mL oral solution for sleep onset insomnia in children and adolescents aged 6–17 years with attention-deficit hyperactivity disorder (ADHD).
According to a company press release, melatonin has the potential to decrease sleep latency and increase sleep efficiency in children with ADHD and chronic sleep onset insomnia. Children with ADHD are statistically more likely to have sleep onset insomnia than non-ADHD children. The prevalence of sleep onset insomnia in children with ADHD ranges from 25–50% and can affect their mood, attention, behavior, and school performance.
“We welcome the MHRA’s approval for a condition that negatively affects the quality of life for children and adolescents diagnosed with ADHD and increases the burden for support networks,” said Henno Welgemoed, director of medical affairs at Colonis, in the release. “This approval provides a valuable treatment option for children and adolescents suffering with ADHD and sleep onset insomnia, adding further breadth to Colonis’ growing pediatric portfolio while supporting Clinigen Group’s mission to deliver the right medicine to the right patient at the right time.”
Source: Clinigen
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
